Home › Companies › ACRV

Acrivon Therapeutics

Market cap $61.4M 42.9M shares (10-Q, Nov 10, 2026) × $1.43 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. ACR-368 Phase 2b EC Ph2b4Q 2026ACR-368 Phase 2b EC Ph2b, 4Q 2026, material
  2. CDK11 program IND filing1H 2027CDK11 program IND filing, 1H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

AP3

Acrivon Predictive Precision Proteomics (AP3) platform driven by Generative Phosphoproteomics; enables quantification of drug-regulated compound-specific effects and pathway activity in intact cells; suite of tools including AP3 Interactome, AP3 Kinase Substrate Relationship Predictor, AP3 Data Portal, and AP3 Chatbot; applied to oncology drug discovery, patient selection, and indication finding

Targets: CDK1, CDK2, PLK1, CHK1, CHK2, WEE1, PKMYT1, CDK11

Discontinued (1)

Capital (as filed)

Cash
$47.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$30.2M Sep 30, 2026
Operating cash flow
−$12.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$77.8M cash, runway into the fourth quarter of 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (16)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (16 calls)

Every verdict Biotech Distilled has published on Acrivon Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Acrivon Therapeutics (ACRV): Scientific Deep Dive for ACR-2316 and ACR-368 Science is real but the January 2026 ACR-2316 safety data is the single gating event; wait for a clean safety profile before entering.
  2. Buy core ACRV UPDATE: Platform Supported. Acrivon (ACRV) Clears the Bar. ACR-368 hit 39% ORR in biomarker-positive patients and ACR-2316 showed confirmed responses with manageable safety, validating the AP3 platform and de-risking the one-drug-pony fear.
  3. Speculative buy speculative UPDATE: Acrivon (ACRV) Granular Review: Did the Market Just Throw the Baby Out with the Bathwater? The 50% post-data crash appears to be an overreaction to a solvable dosing schedule problem; the 2-on/5-off schedule offers a viable path and the AP3 platform remains clinically supported.
  4. Buy core Insider Alert: Acrivon (ACRV) - Executives Are Eating Their Own Cooking. CEO and CFO open-market purchases at ~$1.68-1.70 four days after the crash support the hypothesis that the sell-off was an overreaction to a solvable dosing problem.
  5. Buy core Update: Acrivon (ACRV) - Catalyst Added: ACRV Takes the Main Stage in Europe. Late-breaking ESGO oral acceptance for ACR-368 data is an external quality stamp that keeps momentum alive while the company optimizes ACR-2316 dosing.
  6. Buy core UPDATE: Acrivon (ACRV) Brings Its Moat In-House. CLIA certification of a wholly-owned diagnostic lab secures IP control, lowers costs, and makes Acrivon a more attractive partner ahead of the ESGO presentation.
  7. Buy core UPDATE: Acrivon (ACRV) - The Late-Breaking Letdown and the Anatomy of a Friday Flush. ESGO presented the same December data cut causing a sell-the-news drop, but the underlying drug efficacy and diagnostic moat are unchanged; momentum traders created a second entry opportunity.
  8. Buy core UPDATE: Acrivon (ACRV) - Officially Cuts the Cord with its Diagnostic Vendor Clean termination of the Akoya/Quanterix diagnostic agreement with no financial penalty consolidates full commercial rights to the OncoSignature test and de-risks future partnerships.
  9. Buy core UPDATE: Acrivon (ACRV) - The Partnership Pitch Takes Shape Ahead of AACR Upcoming AACR data showing synergy with Topo 1 ADCs and checkpoint inhibitors frames Acrivon as a prime partnership target for Big Pharma's ADC and PD-1 franchises.
  10. Buy core UPDATE: Acrivon (ACRV) - RA Capital Just Backstopped the ATM at $1.80 RA Capital's $7M at-market ATM purchase at $1.80 with no warrants or discount signals the anchor holder views current prices as a dislocation and demonstrates the company can raise from its insider syndicate without crashing the tape.
  11. Buy core UPDATE: Acrivon (ACRV) - The 2H 2026 Catalyst Just Got Locked In A prespecified simultaneous interim on both serous all-comer arms in 2H 2026 concentrates the next major catalyst into a defined window, with runway confirmed into Q3 2027 past that event.
  12. Buy core UPDATE: Acrivon (ACRV) - The Dosing Problem That Crashed the Stock Just Got Solved ACR-2316 moves into randomized dose expansion at 120/160 mg on 3-on/4-off with no grade ≥4 TRAEs and three heavily pretreated lung cancer patients past one year, substantially retiring the January tolerability risk.
  13. Buy core UPDATE: Acrivon (ACRV) - The Phase 3 Now Has a Date, and the Runway Reaches It Runway extended to Q4 2027 through expense discipline without a raise, and the ACR-368 confirmatory Phase 3 is now dated to 1H 2027, pushing the large-raise conversation past the 2H 2026 interim.
  14. Buy core UPDATE: Acrivon (ACRV) - The Crown Jewel Posts Its First Complete Response A confirmed complete response in fourth-line squamous NSCLC deepening from a prior PR, plus 1+ year durability in multiple lung patients, validates the AP3 synthetic-lethality logic in a tumor type where WEE1-class drugs have never shown single-agent activity.
  15. Hold UPDATE: Acrivon (ACRV) - The Oncology Company Just Bought an Autoimmune Drug Acquiring a JAK1 inhibitor for an undisclosed cash price weeks before the make-or-break serous interim splits capital and management attention before the binary readout, warranting a step back to Hold until the interim data and deal cost are known.
  16. Hold UPDATE: Acrivon (ACRV) - The Going-Concern Clock Starts Ticking Going-concern language in the Q3 10-Q and a same-evening S-3 filing confirm a raise is coming; the serous interim in Q4 2026 still lands before the cash runs out, but new money should wait for the interim data to set financing terms.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 17, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)